|
Abnova Corporation CEO Dr. Wilber Huang is invited to speak at 第9回がん新薬開発合同シンポジウム がん治療の未来戦略 held in Tokyo, Japan. Dr. Huang’s speech highlights the iTIL cell therapy for solid tumors.
Invited Speaker: Wilber Huang, MD Topic: iTIL Cell Therapy for Solid Tumors Date: October 11th, 2019 Venue: Iino Hall & Conference Center, Japan |
+886-2-87511888
sales@abnova.com
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)